share_log

Goldman Sachs Maintains Buy on Guardant Health, Lowers Price Target to $45

Goldman Sachs Maintains Buy on Guardant Health, Lowers Price Target to $45

高盛维持对Guardant Health的买入,将目标价下调至45美元
Benzinga Real-time News ·  2023/02/06 09:52

Goldman Sachs analyst Matthew Sykes maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $70 to $45.

高盛分析师马修·赛克斯维持卫士健康(纳斯达克:GH)的买入,并将目标价从70美元下调至45美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发